Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?".

"T-body" or chimeric antigen receptor (CAR) technology, which combines the specificity of an antibody with the homing, tissue penetration, and target cell destruction of T cells, was first described in 1993. After many years of unmet promise, significant improvements in gene transfer, including the development of efficient retroviral vectors for transduction of human T cells, and better understanding of immunological pathways and immune cell interactions, are allowing this technology to reach a critical phase of evaluation, in which we will learn whether the approach can truly meet expectations. In this review we summarize the concept of CAR-based immunotherapy, describe the steps accomplished, and outline the future progress we need to make if this approach is truly to improve cancer immunotherapy.

[1]  S. Riddell,et al.  Safety and immunologic effects of IL-15 administration in nonhuman primates. , 2009, Blood.

[2]  D. Campana,et al.  Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[3]  H. Heslop,et al.  T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. , 2009, Blood.

[4]  Hao Liu,et al.  Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[5]  Michel Sadelain,et al.  The promise and potential pitfalls of chimeric antigen receptors. , 2009, Current Opinion in Immunology.

[6]  P. Katsikis,et al.  Memory T cells need CD28 costimulation to remember. , 2009, Seminars in immunology.

[7]  S. Rosenberg,et al.  Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Hao Liu,et al.  Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma , 2008, Nature Medicine.

[9]  Bruce L. Levine,et al.  Adoptive immunotherapy: good habits instilled at youth have long-term benefits , 2008, Immunologic research.

[10]  Jinjuan Wang,et al.  Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. , 2008, Blood.

[11]  F. Bushman,et al.  Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. , 2008, The Journal of clinical investigation.

[12]  D. Venzon,et al.  Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets , 2008, The Journal of experimental medicine.

[13]  J. Sampson,et al.  Selective modification of antigen-specific T cells by RNA electroporation. , 2008, Human gene therapy.

[14]  E. Shpall,et al.  System Sleeping Beauty the Redirecting Specificity of T-cell Populations for Cd19 Using Cited Articles Citing Articles E-mail Alerts Redirecting Specificity of T-cell Populations for Cd19 Using the Sleeping Beauty System , 2022 .

[15]  S. Rosenberg,et al.  Adoptive cell transfer: a clinical path to effective cancer immunotherapy , 2008, Nature Reviews Cancer.

[16]  M. Suresh,et al.  Effects of IL-7 on memory CD8 T cell homeostasis are influenced by the timing of therapy in mice. , 2008, The Journal of clinical investigation.

[17]  J. Wagner,et al.  Sleeping Beauty transposon-mediated engineering of human primary T cells for therapy of CD19+ lymphoid malignancies. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[18]  Erwin G. Van Meir,et al.  Engineering human tumor-specific cytotoxic T cells to function in a hypoxic environment. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[19]  Mike Gough,et al.  Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. , 2008, The Journal of clinical investigation.

[20]  J. Timmerman,et al.  Interleukin-21: biology and application to cancer therapy. , 2008, Expert opinion on biological therapy.

[21]  M. Martelli,et al.  NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation. , 2008, Blood cells, molecules & diseases.

[22]  H. Heslop,et al.  Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. , 2007, Blood.

[23]  M. Stastny,et al.  Medulloblastomas Expressing IL13Rα2 are Targets for IL13-zetakine+ Cytolytic T Cells , 2007, Journal of pediatric hematology/oncology.

[24]  H. Heslop,et al.  Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. , 2007, Blood.

[25]  C. Rooney,et al.  Gene-engineered varicella-zoster virus reactive CD4+ cytotoxic T cells exert tumor-specific effector function. , 2007, Cancer research.

[26]  M. Eberl,et al.  Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. , 2007, Cancer research.

[27]  R. Gilbertson,et al.  Regression of experimental medulloblastoma following transfer of HER2-specific T cells. , 2007, Cancer research.

[28]  M. Slovak,et al.  Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[29]  Hiroshi Yamamoto,et al.  γδ T cells: firefighters or fire boosters in the front lines of inflammatory responses , 2007, Immunological reviews.

[30]  Alfred L George,et al.  PiggyBac transposon-mediated gene transfer in human cells. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[31]  H. Heslop,et al.  T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. , 2006, Blood.

[32]  David D. Smith,et al.  CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. , 2006, Cancer research.

[33]  Gang Wang,et al.  A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer , 2006, Clinical Cancer Research.

[34]  S. Rosenberg,et al.  Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.

[35]  M. Brenner,et al.  Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells , 2006, Leukemia.

[36]  Clelia Di Serio,et al.  Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration , 2006, Nature Biotechnology.

[37]  S. Sleijfer,et al.  Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  S. Rosenberg,et al.  IL-7 Administration to Humans Leads to Expansion of CD8+ and CD4+ Cells but a Relative Decrease of CD4+ T-Regulatory Cells , 2006, Journal of immunotherapy.

[39]  P. Burkett,et al.  Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis. , 2006, Annual review of immunology.

[40]  S. Rosenberg,et al.  IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. , 2006, Blood.

[41]  Franco Locatelli,et al.  Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  H. Heslop,et al.  A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[43]  S. Rosenberg,et al.  Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells , 2005, The Journal of experimental medicine.

[44]  D. Campana,et al.  Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. , 2005, Blood.

[45]  C. Rooney,et al.  Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis. , 2005, Blood.

[46]  H. Heslop,et al.  An inducible caspase 9 safety switch for T-cell therapy. , 2005, Blood.

[47]  S. Rosenberg,et al.  Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  Weiping Zou,et al.  Immunosuppressive networks in the tumour environment and their therapeutic relevance , 2005, Nature Reviews Cancer.

[49]  Adrian P Gee,et al.  Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes. , 2005, Blood.

[50]  S. Rosenberg,et al.  Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. , 2005, Blood.

[51]  H. Heslop,et al.  Cytotoxic T Lymphocyte Therapy for Epstein-Barr Virus+ Hodgkin's Disease , 2004, The Journal of experimental medicine.

[52]  S. Rosenberg,et al.  Transfer Therapy Cancer Regression in Patients Receiving Cell Lymphocyte Clonotypes Correlates with Cutting Edge: Persistence of Transferred , 2022 .

[53]  H. Jürgens,et al.  Human γδ T cells as mediators of chimaeric‐receptor redirected anti‐tumour immunity , 2004 .

[54]  D. Campana,et al.  Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia , 2004, Leukemia.

[55]  E. Wherry,et al.  Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells , 2003, Nature Immunology.

[56]  M. V. D. van den Brink,et al.  IL-7 enhances peripheral T cell reconstitution after allogeneic hematopoietic stem cell transplantation. , 2003, The Journal of clinical investigation.

[57]  Steven A. Rosenberg,et al.  Adoptive-cell-transfer therapy for the treatment of patients with cancer , 2003, Nature Reviews Cancer.

[58]  L. Naldini,et al.  Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence. , 2003, Blood.

[59]  J. Burrows,et al.  Ex Vivo Analysis of T-Cell Responses to Epstein-Barr Virus-Encoded Oncogene Latent Membrane Protein 1 Reveals Highly Conserved Epitope Sequences in Virus Isolates from Diverse Geographic Regions , 2003, Journal of Virology.

[60]  A. Hagenbeek,et al.  Safety of retroviral gene marking with a truncated NGF receptor , 2003, Nature Medicine.

[61]  S. Forman,et al.  T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. , 2003, Blood.

[62]  Christof von Kalle,et al.  A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. , 2003, The New England journal of medicine.

[63]  A. Wu,et al.  Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy. , 2003, Cytotherapy.

[64]  H. Heslop,et al.  Is retroviral gene marking too dangerous to use? , 2003, Cytotherapy.

[65]  J. Thompson,et al.  Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[66]  F. Marincola,et al.  Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. , 2002, Human gene therapy.

[67]  J. Massagué,et al.  Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. , 2002, Blood.

[68]  C. Rooney,et al.  Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. , 2002, Blood.

[69]  Michel Sadelain,et al.  Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor , 2002, Nature Biotechnology.

[70]  S. Rosenberg,et al.  Transduction of an IL-2 Gene into Human Melanoma-Reactive Lymphocytes Results in Their Continued Growth in the Absence of Exogenous IL-2 and Maintenance of Specific Antitumor Activity , 2001, The Journal of Immunology.

[71]  C. Bollard,et al.  Targeting of GD2‐positive tumor cells by human T lymphocytes engineered to express chimeric T‐cell receptor genes , 2001, International journal of cancer.

[72]  M. Caligiuri,et al.  Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset , 2001 .

[73]  M. Caligiuri,et al.  Human natural killer cells : a unique innate immunoregulatory role for the CD 56 bright subset , 2001 .

[74]  V. Pathak,et al.  Design of retroviral vectors and helper cells for gene therapy. , 2000, Pharmacological reviews.

[75]  S. Jameson,et al.  Interleukin-7 mediates the homeostasis of naïve and memory CD8 T cells in vivo , 2000, Nature Immunology.

[76]  D. Scadden,et al.  Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. , 2000, Blood.

[77]  J. Metcalf,et al.  Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. , 2000, Blood.

[78]  V. Diehl,et al.  Characterization of a chimeric T-cell receptor with specificity for the Hodgkin's lymphoma-associated CD30 antigen. , 1999, Journal of immunotherapy.

[79]  A. Lawson,et al.  Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. , 1998, Journal of immunology.

[80]  D. Srivastava,et al.  Infusion of Cytotoxic T Cells for the Prevention and Treatment of Epstein-Barr Virus–Induced Lymphoma in Allogeneic Transplant Recipients , 1998 .

[81]  A. van den Berg,et al.  Immune escape mechanisms in Hodgkin's disease. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[82]  D. Srivastava,et al.  Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. , 1998, Blood.

[83]  C. Bordignon,et al.  HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. , 1997, Science.

[84]  Malcolm K. Brenner,et al.  Long–term restoration of immunity against Epstein–Barr virus infection by adoptive transfer of gene–modified virus–specific T lymphocytes , 1996, Nature Medicine.

[85]  F. Gage,et al.  In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector , 1996, Science.

[86]  Evelina Mazzolari,et al.  Gene Therapy in Peripheral Blood Lymphocytes and Bone Marrow for ADA− Immunodeficient Patients , 1995, Science.

[87]  R. Krance,et al.  Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation , 1995, The Lancet.

[88]  S. Rosenberg,et al.  Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. , 1994, Journal of the National Cancer Institute.

[89]  Z. Eshhar,et al.  Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[90]  K. Cornetta,et al.  Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. , 1990, The New England journal of medicine.

[91]  A. Miller,et al.  Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection , 1990, Molecular and cellular biology.

[92]  D. Scadden,et al.  Prolonged survival and tissue trafficking following adoptive transfer of CD 4 z gene-modified autologous CD 4 1 and CD 8 1 T cells in human immunodeficiency virus – infected subjects , 2022 .